Biotech · Private company
Anchiano Therapeutics Israel Ltd.
Track this companyFree. Adds Anchiano Therapeutics Israel Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- BC-819/PEIPhase 2 · Superficial Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Biological/Vaccine: BC-819Phase 2 · Pancreas, AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DTA-H19Phase 2 · Pancreatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- inodiftagene vixteplasmidPhase 2 · Non-muscle Invasive Bladder Cancer (NMIBC)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCPHASE2 · TERMINATED · started Mar 20, 2019ClinicalTrials.gov NCT03719300 · fetched Nov 12, 2026
- Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic AdenocarcinomaPHASE2 · TERMINATED · started Sep 1, 2011ClinicalTrials.gov NCT01413087 · fetched Nov 12, 2026
- Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic CancerPHASE1_PHASE2 · COMPLETED · started Aug 1, 2009ClinicalTrials.gov NCT00711997 · fetched Nov 12, 2026
- Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder CancerPHASE2 · COMPLETED · started Jan 1, 2008ClinicalTrials.gov NCT00595088 · fetched Nov 12, 2026